Novavax Push For COVID-19 Vaccine Manufacturing Capacity Delays Flu Vaccine Application

As CEO Erck touts that its COVID vaccine has the 'best data,' Novavax prepares to enter Phase III trials and inks deal with Serum Institute to boost production even as its 'almost a perfect flu vaccine' remains on hold.

Syringe vaccine and vaccine production. Mass-produced syringes with the vaccine contained in it. The new syringes are labelled with the word “vaccine” and the needles have a grey safety lid on them.
Novavax CEO Stanley Erck discussed his company's vaccine portfolio 10 September

Manufacturing capacity shifting to COVID-19 vaccines is delaying Novavax, Inc.’s regulatory filings for its flu vaccine, CEO Stanley Erck said.

Even as the firm builds production capacity for its investigational coronavirus vaccine through a deal with Serum Institute of...

More from Vaccines

More from Pink Sheet